Background Paediatric FMF-patients living in Turkey show a higher proportion of severe disease compared to Turkish children born and raised in Germany1.
Objectives To assess differences in the course of FMF in adults living in Turkey and Germany.
Methods Adult patients suffering from FMF according to the Livneh criteria2 with Turkish ancestry were prospectively included in the study in two university hospitals in Ankara, Turkey (TR) and Herne, Germany (D). A structured interview and the Turkish WHOQOL-BREF were performed.
Results 61 patients were included (TR:31/D:30). The two groups were significantly different in the following aspects (mean±SD): percentage of patients on colchicine treatment (TR:100%/D: 83.3%,p=0.02), daily colchicine dosage in mg among patients taking colchicine (TR: 1.6±0.7/D:1.15±0.7,p=0.009), duration of disease (TR:15.5±9.5/D:22.4±8.2y,p=0.003). In other aspects examined there was no significant difference. The groups were similar in terms of age at study inclusion (TR:30.9±10.8/D:34.2±10.5y), age at onset of FMF symptoms (TR: 15.4±11.3/D:11.8±6.5y), female sex (TR: 74%/D:60%), FMF-severity according to the score by Pras et al.3 (TR: 6.6±2.3/D: 6.4±1.9) and the 4 domains of the WHOQOL-BREF (expressed on a 0-100 scale) physical health (TR:57.5±19/D:59.1±20.4), psychological health (TR: 61.3±17.4/D:66.4±19.2), social relationship (TR:66.4±21.7/D:67±23.3), environment (TR: 62.2±18.4/D:68.5±16.8). There was no relevant and significant correlation between FMF-severity and QOL. In most domains (exception: better psychological health of FMF-patients) QOL in the patients studied was comparable to that of Turkish patients on hemodialysis4.
Conclusions 16.7% of FMF-patients of Turkish origin living in Germany included in our study are not taking colchicine (TR: 0%). The average colchicine-dosage in Germany is lower and patients examined in Germany had a longer duration of disease. However, there was no significant difference in disease activity (assessed by the Pras-score) and QOL (assessed by the WHOQOL-BREF) between FMF patients in the two nations. No relevant correlation between FMF disease severity and QOL could be found.
Özen S et al. Ann Rheum Dis 2008;68:246
Livneh A et al. Arthritis Rheum 1997;40:1879
Pras E et al. Am J Med Genet 1998;75:216
Sertoz OO et al. Ther Apher Dial 2009;13:366
Disclosure of Interest A. Giese: None Declared, A. Örnek: None Declared, M. Kurucay: None Declared, L. Kiliç: None Declared, S. Şendur: None Declared, S. Kiraz: None Declared, E. Lainka Grant/Research support from: Part of the study was supported by a grant from the German ministry of education and research (BMBF 01GM08104), B. Henning: None Declared